The Fibro Guy Logo Black
The Fibro Guy Logo Black
Consultation

Ozempic, Hypermobility and Chronic Pain: What the Evidence Actually Says

Medical injection pen device on a clean surface with notepad and stethoscope, representing GLP-1 medication for chronic pain management
Adam Foster
Latest posts by Adam Foster (see all)

Ozempic, Hypermobility and Chronic Pain: What the Evidence Actually Says

You’ve probably seen the headlines. Ozempic is being described as a wonder drug. It’s in celebrity gossip columns, it’s on the news, it’s in your social media feed and, increasingly, it’s being discussed in chronic illness communities with a mix of genuine hope and real apprehension. For those of us who work with people living with fibromyalgia, Ehlers-Danlos syndrome, and persistent chronic pain, the questions have been coming in thick and fast. Does it help with pain? Could it make things worse? Should I be asking my doctor about this?

So, that’s what this article is about. We’re going to go through the actual science, the specific risks that apply to those with hypermobility and EDS, the evidence for fibromyalgia specifically, and the honest practical picture, because there is genuinely interesting stuff here alongside some real reasons for caution. This isn’t going to be a cheerleading piece or a scaremongering one, it’s going to be an evidence-based look at where things actually stand in early 2026.

Fair warning: this is a long one. The topic covers a lot of ground, and I’d rather give you the full picture than a five-hundred word summary that leaves out the stuff that matters most for your particular situation. When it comes to a drug class this powerful with this many moving parts, you deserve the detail.

What Are GLP-1 Receptor Agonists?

GLP-1 stands for glucagon-like peptide-1, which is a hormone your gut naturally produces when you eat. Its main job is to stimulate insulin release, suppress glucagon (the hormone that raises blood sugar), slow down how quickly your stomach empties, and signal to your brain that you’re full. It’s a key player in appetite regulation and blood sugar control. GLP-1 receptor agonists are drugs that mimic this hormone, binding to the same receptors and triggering the same responses, but with a much longer duration of action than the natural version.

Semaglutide is the one you’ve heard most about. It’s sold as Ozempic (weekly injection for type 2 diabetes) and Wegovy (higher-dose weekly injection specifically licensed for weight management). Liraglutide (Victoza, Saxenda) and tirzepatide (Mounjaro), which also targets GIP receptors, are others in the same class. Now, these drugs were originally developed for type 2 diabetes management but have become widely used for obesity after trials showing substantial weight loss, sometimes in the range of 15 to 20 percent of body weight [13].

Now, the reason these drugs have crossed into the chronic pain conversation is the emerging evidence that GLP-1 receptors don’t just exist in the gut and pancreas. They’re found in the brain, in immune cells, in joint tissue, and in the spinal cord. And that discovery has opened up a whole series of questions about whether these drugs might have effects well beyond blood sugar and body weight, and the pain science community has started paying close attention [1, 9].

The Three Ways They Might Reduce Pain

Pathway One: Mechanical Load and Weight Reduction

Now, the most obvious potential mechanism is the simplest one. Less body weight means less mechanical force through weight-bearing joints, particularly the knees and hips. And this is not a trivial effect. The STEP 9 trial found that semaglutide reduced both body weight and knee osteoarthritis pain compared to placebo, and a large observational study using data from the Shanghai Osteoarthritis Cohort found that people on GLP-1 receptor agonists had a significantly lower rate of knee surgery, 1.7 percent compared to 5.9 percent in the non-GLP-1 group, with weight loss accounting for about 32 percent of that protective effect [22].

But here’s the thing, the weight loss pathway alone doesn’t explain everything. And for those with fibromyalgia, where the central nervous system is the primary driver of pain rather than joint loading, weight reduction by itself is unlikely to be the whole story. We cover the complex relationship between what actually drives chronic pain in fibromyalgia and hypermobility in detail elsewhere, but the short version is: central sensitisation doesn’t care how much you weigh.

Pathway Two: Anti-inflammatory Effects

This one is more interesting, and the evidence is actually reasonably solid, at least for inflammatory markers in metabolic disease. Semaglutide has been shown in multiple studies to reduce TNF-alpha, IL-6, and C-reactive protein, which are key inflammatory signalling molecules [5, 23]. A 2024 meta-analysis looking at 13 randomised controlled trials found significant CRP reductions in people with type 2 diabetes taking semaglutide [23]. A separate study of 40 men with type 2 diabetes found that 1mg per week for six months reduced both TNF-alpha and IL-6 significantly [5].

The American College of Rheumatology’s 2025 annual conference (ACR Convergence 2025) added to this picture, with data suggesting that patients on GLP-1 drugs had fewer rheumatic disease flares and that those with osteoarthritis saw greater improvements in pain and function compared to those on SGLT2 inhibitors, another diabetes drug class [11]. The data also pointed to a lower risk of developing immune-mediated inflammatory diseases in people taking GLP-1s over time [11].

However, we need to be careful here. Almost all of this data comes from people with type 2 diabetes or obesity. We don’t have equivalent high-quality data for fibromyalgia or EDS specifically, and the inflammatory profile in those conditions is different to the metabolic inflammation these studies were mostly looking at. The signal is interesting. However, it’s just not a direct translation.

Those of us in the hypermobility and fibromyalgia space are well aware of the complex mast cell and inflammatory picture in fibromyalgia, and it’s worth keeping in mind that the anti-inflammatory effects of GLP-1 drugs have been studied in a pretty specific metabolic context, not in the kind of neuroinflammatory picture we see in central sensitisation states. That distinction matters.

Pathway Three: Direct Neural Pain Modulation

This is the pathway that has the research community most excited, and also the one that’s most speculative at this point. GLP-1 receptors have been found on spinal cord microglia, which are the brain and spinal cord’s immune cells, and activation of those receptors appears to shift microglia from a pro-inflammatory M1 state to an anti-inflammatory M2 state [2, 16]. That shift is important because microglial activation is implicated in how the nervous system amplifies pain signals in conditions like fibromyalgia.

A 2014 study in the Journal of Neuroscience found that activating spinal GLP-1 receptors specifically suppressed pain hypersensitivity, and that this appeared to work partly through beta-endorphin release mediated by IL-10 [7]. A 2024 study found that GLP-1 peptides directly inhibit the TRPV1 pain receptor, which is sometimes called the “chilli pepper” receptor because it’s the one that responds to capsaicin [6]. Now, TRPV1 is also deeply involved in central sensitisation and hyperalgesia in fibromyalgia, so that’s a mechanistically plausible connection.

And semaglutide specifically has been shown to reduce neuropathic pain in diabetic rats by inhibiting spinal neuroinflammation [8], and a 2025 review in the Korean Journal of Pain concluded that GLP-1 receptor agonists have real potential in neuropathic pain management [20].

So why aren’t we more excited about this? Well, because almost all of it is from animal models. The human clinical data for direct neural pain modulation from GLP-1 drugs is very limited. Dr Jarred Younger, a prominent researcher in neuroinflammation and chronic pain, has publicly stated that semaglutide does reduce chronic pain via these three pathways, but also acknowledged that “all the semaglutide and microglia studies I know of are in animal models… there’s still another step that needs to be taken.” That caveat matters enormously, and it’s one we’ll come back to.

The Fibromyalgia Evidence

When it comes to fibromyalgia specifically, the honest answer is that we’re at very early days. So, the most significant piece of direct evidence published so far is a 2025 rat study from the Journal of Neuroimmune Pharmacology [2], and I want to be clear upfront: it’s a rat study. That doesn’t mean it’s worthless, it means we need to interpret it carefully.

The study used a reserpine-induced fibromyalgia model in rats, which is a well-established way of producing fibromyalgia-like symptoms in animals. Semaglutide was given at three different doses over 14 days, and the results were genuinely striking. It dose-dependently reversed pain hypersensitivity to both mechanical and thermal stimuli, reduced depression-like behaviour, and improved motor coordination. The mechanism appeared to involve the cAMP/PKA/p-CREB signalling pathway and that M1-to-M2 microglial shift we mentioned earlier. TNF-alpha was reduced by 38 percent, a pro-inflammatory enzyme called iNOS was reduced by 43 percent, and the anti-inflammatory cytokine IL-4 increased by 2.55-fold [2].

That’s a genuinely interesting mechanistic story. But, and this is a significant but, these were male rats, this is the first study of its kind for fibromyalgia, there was no comparison to existing approved fibromyalgia treatments, and the dose to effect relationship in rats doesn’t translate directly to humans. We’ve seen plenty of exciting animal models in chronic pain research that haven’t made it through to clinical practice. This is a promising first signal, nothing more, and it would be wrong to tell people otherwise.

There’s also an important comparison worth making here. For those who’ve read our article on low dose naltrexone for fibromyalgia, you’ll know that LDN also works through microglial mechanisms, has some decent human trial data, and has been around in the clinical setting for years. GLP-1 drugs are not at that stage for fibromyalgia, not even close. They don’t yet have an approved fibromyalgia indication, they’re substantially more expensive, and the human evidence is not there yet.

Patient reports from online communities are mixed, sometimes interestingly so. Some people with fibromyalgia report significant reductions in pain and flare frequency: one individual wrote that they “unexpectedly discovered that it significantly alleviated my fibromyalgia symptoms” and had experienced reduced pain since starting the medication. Others report no meaningful change, and at least one person who lost 120 pounds on the medication reported that their fibromyalgia symptoms actually intensified rather than improved, which rather pokes a hole in the simple weight loss hypothesis.

Well, this variability isn’t surprising when you consider how heterogeneous fibromyalgia is as a condition. The mechanisms driving chronic pain in fibromyalgia vary considerably between individuals, some people have a dominant neuroinflammatory picture, others have a more autonomic or peripheral component, and a drug that targets one pathway isn’t going to work uniformly. However, the broader systematic review across all presentations.

The broader systematic review of GLP-1 drugs in pain conditions [9] and the 2025 comprehensive review in the Journal of Headache and Pain [1] both conclude that the mechanistic case is plausible and interesting, but that human clinical trials with pain as the primary outcome are needed before we can make firm recommendations. There are no Phase III RCTs for pain as a primary outcome endpoint outside of IBS. That’s the honest state of play.

Why Those With Hypermobility and EDS Need to Think Carefully

This section is the most important one in the article for many of you reading this. Because whilst the potential pain benefits are interesting, there are specific reasons why the hypermobility and Ehlers-Danlos population needs to approach GLP-1 drugs with considerably more caution than the general public. Let me take you through them one by one.

Gastroparesis: A Serious Concern

GLP-1 receptor agonists slow gastric emptying. That’s actually one of the mechanisms through which they help with weight loss and blood sugar control, food moves through your stomach more slowly, you feel full sooner, and the glucose hit from a meal is blunted. For most people, this translates to mild nausea, especially at the start of treatment. For some people, it can progress to gastroparesis, a condition where stomach emptying is significantly impaired.

Here’s why this matters so much for those with hypermobility and EDS. Gastroparesis and broader gastrointestinal dysmotility are already very common in EDS. A 2023 gene enrichment analysis found significant enrichment of EDS-related genes in people with idiopathic gastroparesis, suggesting a genuine biological link rather than coincidence [18]. The FDA has updated labelling for both Ozempic and Wegovy to warn of gastroparesis risk, and there are case reports in EDS communities of people developing persistent gastroparesis on GLP-1 drugs, in some cases symptoms that continued even after stopping the medication.

So you’re potentially adding a drug that slows gastric emptying to a body that already has a predisposition to gastric dysmotility. However, that’s a combination that warrants serious thought and close monitoring if you’re going to pursue it. This isn’t a reason to categorically rule it out, but it is a reason to have a thorough conversation with a gastroenterologist who understands EDS, ideally before starting, not after problems develop. Understanding the full range of hypermobility-related symptoms including the GI picture is essential context for that conversation.

Muscle Loss and Joint Stability: The Issue That Doesn’t Get Enough Attention

This one doesn’t get nearly as much coverage as it should, and for those with hypermobility it’s arguably the most significant concern of all. When people lose weight on GLP-1 receptor agonists, not all of that weight is fat. Studies suggest that somewhere between 15 and 40 percent of the total weight lost on these medications is lean body mass, meaning muscle [10].

For the average person trying to lose weight, some muscle loss is an acceptable trade-off. However, for those with Ehlers-Danlos Syndrome or hypermobility spectrum disorder, it’s potentially quite a different calculation. When you have connective tissue that doesn’t do its stabilising job properly, muscle is your primary defence against subluxations, dislocations and joint instability. It’s one of the main things that holds you together.

We’ve written at length about why weight loss can sometimes increase subluxation frequency in those with hypermobility, because losing the muscle tissue that was providing joint support takes away a layer of protection. The same principle applies here, possibly more acutely given the rate at which GLP-1 drugs can produce weight loss.

Now, the mitigation strategies are clear enough: high-protein intake to spare muscle, and resistance training to preserve or build lean mass alongside the medication. The evidence for creatine supplementation as a muscle-sparing tool in this population is also worth knowing about, and we’ve covered creatine’s specific benefits for hypermobility and EDS in detail. But the honest truth is that these mitigation strategies require a level of physical capacity and exercise tolerance that many people with EDS simply don’t have. Exercise with hypermobility is already a complex business, and adding significant weight loss to the picture requires careful coordination.

A 2025 observational study specifically looking at GLP-1 drug use in people at high risk for sarcopenia found concerning signals even with mitigation attempts [10]. Preclinical evidence is more mixed, with some animal models showing muscle preservation under certain conditions [3], but the clinical human data from high-risk populations is less reassuring.

MCAS Interactions: A Two-Sided Story

Mast cell activation syndrome is common in EDS, and when it comes to GLP-1 drugs and mast cells, the interaction is genuinely complicated. But there are case reports suggesting that GLP-1 receptor agonists may actually stabilise mast cells in some people, with some clinicians working in this space reporting positive responses in patients with ME/CFS, fibromyalgia, and long COVID who have a significant mast cell component. Drs Kaufman and Ruhoy, who treat complex post-viral and inflammatory conditions, have described the results in some of their patients as “eye-opening.”

However, other people with MCAS report worsening GI symptoms on GLP-1 drugs, and since the gastrointestinal tract is a major site of mast cell activity, the slowed gastric emptying effect can compound existing issues. We cover what mast cell activation syndrome actually involves and its connection to fibromyalgia in separate articles if you want the full background.

The bottom line here is that the MCAS response to GLP-1 drugs appears to be highly individual. There’s no reliable way to predict in advance whether someone will be a positive responder or will experience worsening symptoms, which is another argument for extreme caution and close monitoring if trialling these drugs in someone with known MCAS.

Surgical Risk

And a slightly different but important consideration: the American Society of Anesthesiologists recommends stopping GLP-1 receptor agonists one week before any planned surgery, because the slowed gastric emptying increases the risk of aspiration during anaesthesia. People with EDS already face higher surgical risks due to factors including tissue fragility and poor wound healing. This is worth factoring in when weighing whether to start these medications, since it introduces a complication into surgical planning that didn’t exist before.

Rhabdomyolysis: Rare but Worth Knowing

There is a published case report of rhabdomyolysis, a serious condition involving rapid breakdown of muscle tissue, associated with semaglutide use [15]. This is a single case report and the first of its kind, so we can’t draw strong conclusions from it, but it’s notable for a population that already tends to have issues with muscle function and fatigue. It warrants monitoring, particularly if someone notices unusual muscle pain, weakness, or dark urine while on the medication.

I’ll be honest, I don’t know exactly why this occurred in that particular case, and neither does the evidence at this point. But for those already dealing with significant exercise tolerance issues and muscle-related symptoms, it’s another variable to be aware of.

The Osteoarthritis Connection

When it comes to osteoarthritis, the evidence for GLP-1 receptor agonists is more substantial than for fibromyalgia, though still not without contradictions. This matters for the hypermobility community because many people with EDS and hypermobility develop OA-type joint changes earlier in life due to the chronic mechanical stress of unstable joints, and the overlap between fibromyalgia and osteoarthritis is well-recognised.

The most striking recent piece of evidence came from a 2026 study published in Cell Metabolism [12], which found that semaglutide appeared to reverse cartilage damage in a mouse model of osteoarthritis, and crucially, this effect was independent of weight loss. The researchers used a pair-feeding control group to rule out the weight effect, and the drug still produced cartilage repair. In a small human component of the same study (n=20), people receiving intra-articular hyaluronic acid injections combined with semaglutide showed thicker cartilage, measurable cartilage growth, and lower pain scores after 24 weeks. That’s very preliminary but it’s a genuine signal.

The Shanghai Osteoarthritis Cohort data also showed slower cartilage loss and lower knee surgery incidence in GLP-1 users [22], and ACR Convergence 2025 found greater pain and function improvements in OA patients on GLP-1s compared to those on SGLT2 inhibitors [11]. The mechanism likely involves GLP-1 receptors found directly in joint tissue, with liraglutide shown to reduce matrix metalloproteinases (enzymes that break down cartilage) and shift macrophages in the joint to an anti-inflammatory state [19].

However, it’s not all positive. A 52-week RCT with 156 randomised patients with knee OA using liraglutide produced significant weight loss but no significant reduction in pain compared to placebo [1]. But that contradicts some of the observational data, and it’s a reminder that OA is a complex condition where weight-independent pain mechanisms can dominate. Not everyone with OA will benefit from this drug class, and the early promise of the mechanistic data hasn’t fully translated into consistent clinical trial results.

What the Bone Health Data Says

Now, the bone health picture was given a lot of attention at the AAOS 2026 Annual Meeting, and the data here is genuinely concerning enough to warrant its own section. A large retrospective analysis presented there looked at GLP-1 receptor agonist use over five years in adults with type 2 diabetes and obesity [4]. The findings showed increased risk of osteoporosis (relative risk 1.29), gout (relative risk 1.12), and, most strikingly, osteomalacia, which is a softening of the bones, with a relative risk of 2.55 [4].

Now, a relative risk of 2.55 for osteomalacia is a big number. And osteomalacia involves inadequate bone mineralisation, and it can cause widespread bone pain and muscle weakness. When it comes to those with hypermobility who are already potentially dealing with significant flare-ups and complex pain patterns, adding a mineralisation disorder to the mix would not be helpful.

However, the mechanism likely involves the combination of weight loss, changes in nutritional absorption due to slowed gastric emptying, and potentially reduced loading on bones (since bones respond to mechanical load by increasing density). There’s also a vitamin D and calcium consideration, since GLP-1 drugs can reduce absorption of fat-soluble vitamins.

A Phase 2 randomised controlled trial published in 2024 specifically looking at bone markers in people taking once-weekly semaglutide found more neutral or slightly beneficial effects on bone formation markers [17], which somewhat contradicts the AAOS observational data. But the AAOS data is from five years of real-world use, not a short-term trial, and the divergence may simply reflect that shorter-term effects on bone markers don’t capture what happens over years of use.

So, for those with hypermobility considering these medications, a baseline DEXA scan, adequate vitamin D and calcium intake, and monitoring of bone density over time seem like reasonable precautions if proceeding. This is another conversation to have with your doctor before starting, not after a fracture.

What Patients Are Actually Reporting

So, patient reports from Reddit and EDS/fibromyalgia forums paint a picture that’s consistent with what the emerging evidence would predict: highly variable, both in terms of outcomes and in terms of which symptoms are affected.

Well, on the positive side, some people with fibromyalgia report what sound like genuine improvements in pain levels and frequency of flares, sometimes unexpectedly so, with one person describing a significant reduction in symptoms that returned when the medication was paused. People with inflammatory joint conditions and OA-type pain seem to have a somewhat higher rate of positive reports, which aligns with the OA-specific evidence.

But on the negative side, gastroparesis and worsening GI symptoms feature prominently in EDS community discussions. The slowed motility issue is not a theoretical concern, it’s affecting real people. At least one person in community forums described developing gastroparesis that significantly impacted their quality of life during the year they were on the medication. Some reports of persistent GI problems after stopping the drug are also circulating, though it’s difficult to establish causality from individual reports.

And the weight-independent pain picture is also interesting. As I mentioned earlier, losing substantial weight doesn’t consistently correlate with fibromyalgia improvement, and some people report their symptoms worsening as they lose weight, which is consistent with what we know about how muscle loss affects joint stability and pain in hypermobility.

But there’s also the question of what dose matters. The clinical researchers who are most optimistic about GLP-1 drugs for chronic pain, including Dr Ilene Ruhoy, are using considerably lower doses than the obesity trials, sometimes 5 to 10 times lower, around 0.25 to 0.5mg per week rather than the 2.4mg used in weight loss trials. The logic is that you’re targeting neural mechanisms rather than dramatic weight loss, so you might avoid many of the risks associated with the higher doses while still getting some of the anti-inflammatory and pain-modulating effects. This is intriguing but it’s very much at the experimental fringes, not established clinical practice.

I should also mention something that I find genuinely fascinating from a research perspective, and I’ll hold my hands up that this is a tangent. The fact that GLP-1 receptors exist in the brain’s reward and satiety circuits means these drugs also appear to reduce addictive behaviours in some people, including alcohol consumption and impulsive eating. Several neurological researchers are now studying GLP-1 drugs for addiction medicine. It’s a reminder that we’re dealing with a hormone that touches a lot of systems we didn’t previously connect it to, and the chronic pain angle is just one of several unexpected directions this research has taken.

Should You Ask Your Doctor About It?

Well, the honest answer depends heavily on your individual situation, and I want to be specific about that rather than giving you a generic “talk to your doctor” response.

If you have a separate qualifying indication, meaning type 2 diabetes or clinically significant obesity, and you don’t have a history of significant gastroparesis or GI dysmotility, it’s entirely reasonable to discuss GLP-1 receptor agonists with your doctor as a potential treatment for that primary indication, whilst being aware of the chronic pain angle as a potential secondary benefit. In this scenario, the risk-benefit discussion is the standard one, plus the additional considerations around muscle loss and bone health that we’ve covered above.

If you don’t have a qualifying indication and you’re looking at these drugs purely for pain management, that’s a significantly harder case to make given the current evidence. Dr Younger is clear that semaglutide should not be prescribed for chronic pain without a separate indication at this stage of the evidence. And effects likely take one to three months to manifest, the drugs are expensive (around £800 to £1000 per month without insurance coverage, and typically not covered for pain indications), and the risks we’ve covered in this article need to be weighed against benefits that are still largely unproven in human clinical trials.

For those with hypermobility and EDS specifically, I’d flag the following as the minimum due diligence before starting these medications:

  • A thorough GI history and ideally gastric emptying assessment if there’s any existing dysmotility
  • Baseline muscle mass measurement (DEXA or similar) given the sarcopenia risk
  • A clear plan for high-protein diet and resistance-based exercise to mitigate muscle loss
  • Baseline bone density if there’s any existing concern
  • Consideration of the nutritional picture specific to hypermobility, since these drugs can affect appetite and nutrient absorption
  • A conversation specifically about MCAS if that’s a feature of your presentation

The medication options for hypermobility and EDS are limited and often unsatisfying, and it’s entirely understandable why people are looking at something new with genuine curiosity. But new doesn’t automatically mean better, and for this particular population the risks aren’t trivial. There are existing medications that get used for chronic pain in these conditions, from amitriptyline for sleep and pain to newer options like the recently approved tonmya for fibromyalgia, and the honest truth is that even those more established treatments have mixed evidence records. GLP-1 drugs are currently a long way further back in the evidence queue.

It’s also worth keeping in mind that there are other things that have decent evidence for both pain and the inflammatory picture in these conditions. Careful pacing has solid evidence behind it. Sleep quality has a direct and well-established relationship with pain levels. The autonomic nervous system plays a huge role in pain modulation and there are interventions targeting it specifically. Fear of movement is one of the most underappreciated drivers of persistent pain in hypermobility, and addressing it doesn’t carry the risks of systemic medication. These aren’t alternatives to exclude the GLP-1 conversation, they’re the base to be building on regardless.

If you are experiencing significant cognitive symptoms alongside your pain, those should be part of the picture too. There’s some early evidence that GLP-1 drugs may have neuroprotective properties in metabolic disease, but again, the EDS-specific data isn’t there yet.

For those who are managing their hypermobility symptoms more broadly, it’s also worth having a read about compression garments for dysautonomia and the role of CO2 tolerance in breathlessness and chronic pain. These are the kinds of evidence-based approaches that tend to get less attention than a new drug, which is a shame.

The Honest Bottom Line

GLP-1 receptor agonists are genuinely interesting drugs. The mechanistic case for effects beyond weight loss and blood sugar, particularly in inflammation and pain modulation, is plausible and supported by some compelling early evidence. The 2025 rat study on fibromyalgia [2], the 2026 OA cartilage data [12], the ACR 2025 rheumatic disease findings [11], and the growing body of neurobiological research all point in the same direction. But the direction isn’t wrong, the evidence just isn’t mature enough yet to make firm clinical recommendations for chronic pain.

For those with hypermobility and EDS, the specific risks around gastroparesis, muscle loss, bone health, and the already-complex GI picture mean that “wait and see” is a completely defensible position in 2026. This isn’t medical cowardice, it’s appropriate caution in the face of a genuinely uncertain evidence base. We have enough experience in the EDS community of things that help the general population creating new problems for this specific population to be appropriately humble about that.

The weight medication picture is something we’ve looked at in relation to fibromyalgia and weight gain and the specific question of weight changes in EDS before, and it’s a complicated space. GLP-1 drugs add a new dimension to that complexity.

What I’d genuinely like to see, and what the field needs, is a properly conducted Phase III randomised controlled trial in fibromyalgia patients, ideally with a sub-group of people with hypermobility and EDS, using low to moderate doses and with muscle mass, GI function, and bone health as pre-specified safety endpoints. We need human data, not more rat studies. Until we have it, the most honest thing I can tell you is that this is a space to watch carefully, not to rush into.

And the people who are most excited about GLP-1 drugs for chronic pain, the clinicians using very low doses in ME/CFS and FM patients, are doing something genuinely interesting. But they’re also aware that they’re operating in a space well ahead of the clinical trial data. That’s a reality worth sitting with before making a decision.

And if you’re weighing whether the potential benefit of these drugs justifies the risks for your situation, then that’s a conversation worth having with a doctor who knows your full picture, not just your weight or your blood sugar. When it comes to a condition as complex as EDS or fibromyalgia, the whole picture always matters.

There’s also a version of this where GLP-1 drugs, at the right dose, for the right person, at the right time, turn out to be genuinely useful for chronic pain. I don’t want to be the person who dismissed something real. But I also don’t want to be the person who sent someone with already-compromised GI motility and joint instability into a situation that made both worse. The evidence doesn’t yet tell us how to reliably identify which camp someone falls into, and until it does, careful individual assessment is the only sensible path.

We’ll keep an eye on this one, and we’ll update this article as new evidence comes in. That’s a promise.

— The Fibro Guy Team —

References

  1. He Y, Xu B, Zhang M, et al. Advances in GLP-1 receptor agonists for pain treatment and their future potential. The Journal of Headache and Pain. 2025;26:44. https://pmc.ncbi.nlm.nih.gov/articles/PMC11869436/
  2. Shafiek MZ, Zaki HF, Mohamed AF, Ibrahim WW. Novel Trajectories Towards Possible Effects of Semaglutide for Amelioration of Reserpine-induced Fibromyalgia in Rats. Journal of Neuroimmune Pharmacology. 2025;20:47. https://pmc.ncbi.nlm.nih.gov/articles/PMC12003577/
  3. Pantazopoulos D, Gouveri E, Papazoglou D, Papanas N. GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? Diabetes Research and Clinical Practice. 2025;219:111960. https://pubmed.ncbi.nlm.nih.gov/41022269/
  4. Wajahath M, et al. GLP Receptor Agonist Use is Associated with Increased Risk of Osteoporosis, Gout and Osteomalacia in Adults with Type 2 Diabetes and Obesity. Presented at AAOS 2026 Annual Meeting. https://aaos-annualmeeting-presskit.org/2026/research-news/studies-explore-glp-1-receptor-agonist-use-and-its-impact-on-long-term-musculoskeletal-health/
  5. Barbagelata L, Nogueira JP, Lobo M, et al. Anti-inflammatory benefits of semaglutide: State of the art. Journal of Clinical & Translational Endocrinology. 2024;36:100341. https://pmc.ncbi.nlm.nih.gov/articles/PMC10992717/
  6. Lee BG, et al. GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation. Experimental & Molecular Medicine. 2024;56:2442-2455. https://pmc.ncbi.nlm.nih.gov/articles/PMC11612315/
  7. Nong G, Xiao YC, Wang YX, et al. Activation of Spinal Glucagon-Like Peptide-1 Receptors Specifically Suppresses Pain Hypersensitivity. Journal of Neuroscience. 2014;34(15):5322-5334. https://pmc.ncbi.nlm.nih.gov/articles/PMC6608999/
  8. Kuthati Y, Huang WH, Lee SO, Wong CS. Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord. Cells. 2024;13(22):1857. https://pmc.ncbi.nlm.nih.gov/articles/PMC11593193/
  9. Halloum W, Al Dughem Y, Pellesi L, Beier D. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. The Journal of Headache and Pain. 2024;25(1):112. https://pmc.ncbi.nlm.nih.gov/articles/PMC11241973/
  10. Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia. Current Nutrition Reports. 2025. https://pubmed.ncbi.nlm.nih.gov/40289060/
  11. ACR Convergence 2025: New Research Highlights Potential of GLP-1 Therapies in Rheumatic Disease Management. American College of Rheumatology. 2025. https://rheumatology.org/press-releases/new-research-at-acr-convergence-2025-highlights-potential-of-glp-1-therapies-in-rheumatic-disease-management
  12. Semaglutide may reverse damage caused by osteoarthritis. Cell Metabolism. 2026 (via ScienceAlert). https://www.sciencealert.com/semaglutide-may-reverse-damage-caused-by-osteoarthritis-study-suggests
  13. Nogrady B. The ‘astounding’ rise of semaglutide and what’s next for weight-loss drugs. Nature. 2026. https://www.nature.com/articles/d41586-026-00228-1
  14. Alharbi S. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic Advances in Endocrinology and Metabolism. 2024;15. https://pmc.ncbi.nlm.nih.gov/articles/PMC10823863/
  15. Prier CC, Felix HM, Hedges MS, Billings SA. Rhabdomyolysis Associated With Semaglutide Therapy: A Case Report. Cureus. 2023;15(12):e50227. https://assets.cureus.com/uploads/case_report/pdf/206675/20231209-9576-1aoaj8y.pdf
  16. Wei J, et al. Microglial Activation of GLP-1R Signaling in Neuropathic Pain. Neural Plasticity. 2021;2021:9923537. https://pmc.ncbi.nlm.nih.gov/articles/PMC8426070/
  17. Hansen MS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised phase 2 trial. eClinicalMedicine. 2024;72:102624. https://pmc.ncbi.nlm.nih.gov/articles/PMC11087719/
  18. Smieszek SP, et al. (idiopathic gastroparesis and EDS gene enrichment). Clinical and Translational Gastroenterology. 2023. Referenced via eds.clinic.
  19. Meurot C, et al. Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? Journal of Orthopaedic Translation. 2022;32:121-129. https://pmc.ncbi.nlm.nih.gov/articles/PMC8888891/
  20. GLP-1 receptor agonists in neuropathic pain. The Korean Journal of Pain. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12221951/
  21. Cañas C, et al. Eosinophilic fasciitis during semaglutide treatment: a case report. Clinical Rheumatology. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10412476/
  22. Chen Y, et al. GLP-1 receptor agonists as disease-modifying therapy for knee OA: Shanghai Osteoarthritis Cohort. Annals of the Rheumatic Diseases. 2023;82:1267-1275. https://pmc.ncbi.nlm.nih.gov/articles/PMC10423473/
  23. Barbagelata L, et al. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2024;11:1379189. https://pmc.ncbi.nlm.nih.gov/articles/PMC11270812/

Read our latest articles

More Articles